



ASX Announcement

ortho·cell

Investor Presentation Orthocell Ltd to present at Broker Meets Biotech

Perth, Australia, 31 March 2026: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to release a copy of the presentation to be delivered by Managing Director **Paul Anderson** at the **WA Life Sciences Broker Meets Biotech event**, held in Perth on 31 March 2026.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H^ACK Director
P: +61 423 139 163
E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au

About Orthocell Limited ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors and recorded initial sales. The Company’s flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand and Canada. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major

products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

ersonal use only



Investor Presentation Broker Meets Biotech

31 March 2026



Disclaimer

This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or

representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward-looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Commercialisation of Remplir™ is on-track

Australian medical technology company with growing international revenue and US market launch of its flagship nerve repair product, Remplir




Fully funded and investing in growth

It is Orthocell's view that it has the required funds for the investments necessary to reach profitability, with the cash balance estimated to stay above the high \$20Ms



US strategy is on-track

Market access activities are clearly defined with execution progressing as planned and sales continuing to build



US market share¹ to reach cash breakeven² is less than 1%

Orthocell estimates that it requires approximately ~5,000 - 6,000 procedures in the US per annum to reach cash breakeven, which is less than 1% of the addressable market

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies
2. Cash breakeven reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions

ersonal use only

Strategy and Focus



Orthocell three-year vision



Establish Orthocell as a global regenerative medicine leader through disciplined growth, operational excellence and a sustainable product pipeline, achieving ASX 300 inclusion



Win in the Americas

Accelerate growth in ANZ and Asia

Scale a global collagen medical device platform

Expand & advance the product pipeline



Grow a high-performance, people-first organisation

Build a data-enabled operating platform

Scale world-class manufacturing capability

End-to-end product development and commercialisation excellence

ersonal use only

Focus in FY26



Gaining market access and growing the customer base of Remplir in the US



Strategic Asia expansion focused on high-return markets



Complete UK and EU launch planning post-Q2 submission for FY27 entry




Recruit specialist talent to deepen expertise and enable scalable growth

Clarity + Execution

ersonal use only

Continued revenue¹ growth

We have maintained constant growth over the last three halves, driven by device sales



1. Revenue comprises sales revenue, interest income and grant income. The R&D tax incentive is excluded.
2. CHGR = compound semi annual growth rate

ersonal use only

ersonal use only

US update



Gaining market access
and growing the customer
base of **Remplir™**


ortho·cell

Remplir™ Nerve repair, made SMRT

Collagen nerve wrap used in the repair of peripheral nerve injuries - reclaiming patients touch, movement and function.



ersonal use only



Guiding predictable outcomes in peripheral nerve repair ←



Mimics the natural epineurium with an absolute collagen wrap



Creates an optimal healing environment for nerve regeneration



Easy to handle and suture sparing, simplifying the surgical process




Protects the repair site from scarring, adhesions, and inflammation

Remplir™ US Peripheral Nerve Repair Trends

Suturing is still the most commonly performed procedure and considered to be the “gold standard” technique for peripheral nerve repair



Over 700,000¹ peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method.



Suturing

- Technically difficult to achieve alignment and tensionless repair
- Induces foreign body reaction leading to chronic inflammation, fibrosis and scarring
- Can lead to suboptimal axonal regeneration and return of function and sensation



1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies

Remplir™ Significant US Market Opportunity

Orthocell has commenced commercial distribution into an estimated US\$1.6 billion total addressable nerve repair market¹ in the US alone




Remplir is not seeking to replace a current dominant market incumbent.
Devices are only used in ~10% of procedures.

Current devices are not widely adopted

- Materials are too rigid, challenging to deploy and make it difficult to manage size differences between nerve ends, leading to compression injuries or neuroma formation
- Fail to fully integrate into native tissue, leaving residual material that impairs the healing process
- Have not significantly improved the consistency of outcomes



Current devices




Remplir™



Pathway to US commercial success

Progress measures are on-track or ahead of target



1. Reference to ASX announcement 4/4/25

2. Measures calculated as of 27/03/26 for all items

3. The remaining five state licenses expected in 2Q CY26, submitted in CY25, are awaiting approval.

4. Percentage of customers who are repeat users to date represents the proportion of clinicians with more than one recorded procedure, excluding those whose first use occurred within the past 4-6 weeks to allow sufficient time for a follow-up case.

ersonal use only


Financials

Path to breakeven and performance
to date



Path to profitability (Cashflow Breakeven)

Breakeven² is achieved at 5,000–6,000 procedures in the US, requiring ~300-400 active surgeons — a number already accessible through the current VAC pipeline




1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies
2. Cash breakeven reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions
3. Average units per procedure reflects observed utilisation from available data, supplemented by clinical assumptions regarding standard use per operation.

Remplir™ US performance since launch


Exceptional early growth since the first sale of Remplir on 26th June 2025 (9 months)

US Remplir Hospitals Cumulative by Quarter




Hospitals have grown to 52 in just over three quarters (26th June, first sale), representing a +273% CQGR² and strong adoption momentum

US Remplir Surgeons Cumulative by Quarter



Surgeons have grown to 48 in just over three quarters (26th June, first sale), representing a +263% CQGR² and strong adoption momentum

US Remplir Unit Sales by Quarter




Unit Sales have grown to above 110-120 per quarter in just over 9 months (26th June, first sale), representing +380% CQGR² and strong adoption momentum

1. Management estimates as at 27 March, 2026
2. CQGR = compound quarterly growth rate

Remplir™ AU/NZ Performance since launch

Significant growth achieved since launch, with near 100% YOY growth, 314 surgeons and 224 hospitals




1. Source: Distributor reported sales data since product launch, including quarterly unit volumes.
2. CQGR = compound quarterly growth rate

Promising New Application for Remplir™ in Prostate Cancer Surgery

Surgeons are using Remplir in prostate surgery to preserve nerve function and improve functional recovery. Potential significant expansion of the Total Addressable Market. Initial patient data expected 2H CY26.

- Australian urologists are using Remplir during prostate cancer surgery to reduce post-surgical complications due to peripheral nerve damage.
- Despite best practice techniques, up to 80% of men experience erectile dysfunction and up to 35% suffer from urinary incontinence due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate.
- Remplir has been used in approximately **200 surgeries in Australia** to assist in improving recovery of erectile function and urinary continence post-surgery.
- **Data from the nerve-sparing procedures and will be released once available.** The Company is investing in further research to build evidence and assist medical education initiatives.
- Prostate cancer remains the most diagnosed cancer among men globally. This promising new application has the potential to significantly expand the global Total Addressable Market for Remplir.



ersonal use only

Investing in growth

US focus and expanding manufacturing capacity





People

Focussed activities through to December 2026

Driving near-term revenue growth through disciplined execution, enabled by a team with proven track record



John Walker

Sales

- On-board Regional Sales Director roles
- Identify distributors or direct reps in key geographies
- Ensure positive customer experience in first surgical cases

Measures of success

- 5 additional distributors onboarded
- 75 additional VAC submissions and 25 approvals
- >40 additional new surgeon customers



Phil Edmondson

Medical Education and Clinical Affairs

- National and regional conference attendance
- Centre of excellence (CoE) focus
- White paper publications

Measures of success

- White papers published
- Clinical usage at all CoE
- >200 additional surgeons trained on product



Kevin Leach

Marketing

- Build on product messaging and content to enable distributors
- Conference booths consistent in brand & messaging with opportunity for hands-on exposure to Remplir

Measures of success

- Sales effectiveness from all existing distributors
- Expedite field team's efforts to onboard new distributors (6 months from onboarding to sales)



Manufacturing expansion – stage 1

Planned capacity upgrades are in place to deliver the volumes estimated and reduce the cost of sale

Stage 1 expansion capital approved

- \$5–5.5M investment to expand the office footprint, increasing manufacturing and warehousing capacity
- Construction beginning in H2CY26 and completion scheduled late 2027

Automation project in the validation phase

- Automated processing and fume-hood upgrades
- No increase to headcount in the medium term
- Enabling 24-hour operations

Secure and reliable supply chain

- Manufacturing upgrades will provide inventory to support expected growth demands
- Inventory availability unaffected during construction with stock held in the US and AU

Designed for scalable production

- Manufacturing cycle times reduced
- Improved device unit operating costs
- Four times the current device manufacturing capacity



ersonal use only

1. Includes acquisition of new machines post-automation project completion

Investment highlights



Best-in-class platform for Bone, Nerve and Tendon repair approved in nine¹ jurisdictions. Compelling supportive clinical data



Product margins retained in-house Manufacturing facility and all IP owned by the company



Growing International Revenues Targeting Large Under Penetrated Markets We have maintained constant growth over the last three halves, driven by device sales



Remplir™ US Strategy is on-track Market access activities are clearly defined with execution progressing as planned and sales continuing to build



With \$49.4M² total cash reserves and a strengthened share register, it is Orthocell's view that we are well-funded for US rollout, with the cash balance estimated to stay above the high \$20Ms

1. Orthocell's collagen platform of products, including Striate+™ and Remplir™.
2. AU\$49.4M as of 31 December 2025, This includes \$7.4 million in cash and cash equivalents and \$42.0 million in term deposits with maturities ranging from 3 to 12 months

Achievements and upcoming catalysts¹



Remplir™ | Nerve repair, made SMRT

US first surgical use	Achieved
US first sales	Achieved
Appoint further US sales team members	Achieved
Appoint first and second distributors in CAN	Achieved
Appoint exclusive distributor in HKG	Achieved
HK first surgical use	Achieved
EU+UK submissions lodged	Achieved
FY25 R&D tax refund (\$3M)	Achieved
Appoint exclusive distributor in UK.....	Achieved

Initial prostate patient data	1H CY26
First sale in Canada	1H CY26
EU+UK market clearance	2H CY26

1. Timelines may be subject to change due to circumstances not under the Company's control

ersonal use only



**Thank you
for attending**



ersonal use only



Authorised for release by
The Board of Directors of Orthocell Limited

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

orthocell.com